Table 3 3 L chemotherapy
Therapy, n (%)a | Australia (N = 9) | Canada (N = 37) | Italy (N = 19) | UK (N = 18) | Overall (N = 83) |
|---|---|---|---|---|---|
Monotherapy | 4 (44.4%) | 28 (75.7%) | 10 (52.6%) | 10 (55.6%) | 52 (62.7%) |
Combination therapyb | 5 (55.6%) | 9 (24.3%) | 9 (47.4%) | 8 (44.4%) | 31 (37.3%) |
Doublet chemotherapy | 5 (100.0%) | 7 (77.8%) | 8 (88.9%) | 6 (85.7%) | 26 (86.7%) |
Triplet chemotherapy | - | 2 (22.2%) | 1 (11.1%) | 1 (14.3%) | 4 (13.3%) |
Missing | - | - | - | 1 | 1 |
Monotherapyc | |||||
Taxanes | 3 (75.0%) | 18 (64.3%) | 8 (80.0%) | 7 (70.0%) | 36 (69.2%) |
Irinotecan | 1 (25.0%) | 8 (28.6%) | - | 1 (10.0%) | 10 (19.2%) |
Ramucirumab | - | 1 (3.6%) | 1 (10.0%) | 1 (10.0%) | 3 (5.8%) |
Fluoropyrimidines | - | 1 (3.6%) | 1 (10.0%) | - | 2 (3.8%) |
Other monotherapy | - | - | - | 1 (10.0%) | 1 (1.9%) |
Doublet chemotherapyc | |||||
Fluoropyrimidine + irinotecan | 5 (100.0%) | 2 (22.2%) | 4 (44.4%) | 5 (71.4%) | 16 (53.3%) |
Fluoropyrimidine + platinum | - | 3 (33.3%) | 3 (33.3%) | - | 6 (20.0%) |
Taxanes + ramucirumab | - | 1 (11.1%) | 1 (11.1%) | 1 (14.3%) | 3 (10.0%) |
Other doublet | - | 1 (11.1%) | - | - | 1 (3.3%) |
Triplet chemotherapyc | |||||
Fluoropyrimidine + platinum + anthracycline | - | 1 (11.1%) | - | - | 1 (3.3%) |
Fluoropyrimidine + platinum + other | - | 1 (11.1%) | 1 (11.1%) | - | 2 (6.7%) |
Other triplet | - | - | - | 1 (14.3%) | 1 (3.3%) |